Results 111 to 120 of about 6,042 (221)

Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis [PDF]

Objectives: The aim of this study was to evaluate the transcriptome of peripheral blood mononuclear cells (PBMCs) derived from patients affected by psoriasis (PSO) and psoriatic arthritis (PSA) following treatment with guselkumab, an interleukin (IL)-23 ...
Barile, Antonio, Bruni, Manfredo, Cipriani, Paola, De Berardinis, Andrea, Esposito, Maria, Fargnoli, Maria Concetta, Lucantonio, Eleonora, Mastrangelo, Mirco, Pellegrini, Cristina, Ruscitti, Piero   +9 more
core   +1 more source

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study [PDF]

Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab.
Chakravarty, Soumya D, Coates, Laura C, Kollmeier, Alexa P, McInnes, Iain B, Mease, Philip J, Rahman, Proton, Rampakakis, Emmanouil, Shawi, May, Tam, Lai-Shan, Xu, Xie L   +9 more
core   +2 more sources

Patch Testing Under Biologics: Six Cases From a Tertiary Centre

Contact Dermatitis, Volume 94, Issue 3, Page 299-301, March 2026.
Alessandra Chiei‐Gallo, Francesca Barei, Angelo V. Marzano, Silvia M. Ferrucci   +3 more
wiley   +1 more source

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study

Rheumatology and Therapy
Introduction Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a “real-life” multicentre patient cohort.
Piero Ruscitti, Giulia Cataldi, Martina Gentile, Alice Dionisi, Paola Volpe, Annacarla Finucci, Lucrezia Verardi, Claudia Di Muzio, Noemi Italiano, Eleonora Celletti, Myriam Di Penta, Ilenia Di Cola, Alessandra Marrelli, Alessia Alfonsi, Francesco Delle Monache, Francesco Cipollone, Marco Gabini, Paola Cipriani   +17 more
doaj   +1 more source

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment

Journal of Inflammation Research
Xiuqing Yuan,1,* Tiantian Xin,1,* Huanhuan Yu,1 Jian Huang,2 Yaohan Xu,1 Caixin Ou,1 Yongfeng Chen1 1Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong Province, People’s Republic of China ...
Yuan X, Xin T, Yu H, Huang J, Xu Y, Ou C, Chen Y   +6 more
doaj  

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome

Turkderm Turkish Archives of Dermatology and Venereology
In this case report, we present a 29-year-old patient with Down syndrome (DS) who manifested both psoriasis and hidradenitis suppurativa (HS) concurrently.
Simge Ünal, Tuğcan Yüksek
doaj   +1 more source

Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience [PDF]

background: the term "super responder" identifies a group of patients who exhibit a rapid and optimal response to biological treatment compared to the overall treated population.
Belcastro A., Bianchi L., Di Raimondo C., Fico A., Galluzzo M., Marcelli L., Paganini C., Savastano L., Talamonti M., Vellucci L.   +9 more
core   +1 more source

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) [PDF]

Introduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis.
Campoli, Marco, Carrera, Carlo G., Carugno, Andrea, Cascio Ingurgio, Ruggero, Costanzo, Antonio, Gaiani, Francesca M., Ibba, Luciano, Malagoli, Piergiorgio, Marzano, Angelo V., Minuti, Anna, Mola, Federica, Narcisi, Alessandra, Strippoli, Davide, Valenti, Mario, Zerbinati, Nicola   +14 more
core   +2 more sources

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. [PDF]

This study aimed to understand treatment response dynamics, including factors associated with favorable response, among patients with moderate-to-severe psoriasis who received guselkumab, adalimumab, or secukinumab. These post hoc analyses used data from
Acciarri, L., Buyze, J., Conrad, C., Egeberg, A., Gorecki, P., Thaçi, D., Wegner, S.   +6 more
core   +1 more source

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Rheumatology and Therapy
Introduction The aim of this study was to evaluate guselkumab efficacy through week 100 in participants with psoriatic arthritis (PsA) and severe disease activity or patient global assessment (PtGA).
Christopher T. Ritchlin, Ennio Lubrano, Maria Sole Chimenti, Evan Leibowitz, Mohamed Sharaf, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Atul Deodhar   +8 more
doaj   +1 more source